<code id='DC6BD3C6FE'></code><style id='DC6BD3C6FE'></style>
      • <acronym id='DC6BD3C6FE'></acronym>
      <center id='DC6BD3C6FE'><center id='DC6BD3C6FE'><tfoot id='DC6BD3C6FE'></tfoot></center><abbr id='DC6BD3C6FE'><dir id='DC6BD3C6FE'><tfoot id='DC6BD3C6FE'></tfoot><noframes id='DC6BD3C6FE'>
      • <optgroup id='DC6BD3C6FE'><strike id='DC6BD3C6FE'><sup id='DC6BD3C6FE'></sup></strike><code id='DC6BD3C6FE'></code></optgroup>
        5. <b id='DC6BD3C6FE'><label id='DC6BD3C6FE'><select id='DC6BD3C6FE'><dt id='DC6BD3C6FE'><span id='DC6BD3C6FE'></span></dt></select></label></b><u id='DC6BD3C6FE'></u>
          <i id='DC6BD3C6FE'><strike id='DC6BD3C6FE'><tt id='DC6BD3C6FE'><pre id='DC6BD3C6FE'></pre></tt></strike></i>
           
   
   
   
 

  
           
   
           
    
           
     
          
       Home / fashion / focus      
           
     
           
      
          focus 
           
      
           
      
           
       2025-10-02 10:29:45 
   
      
           
      
           
                        
          focus  
          
                                   
                 
                                      author：comprehensive   
                                        
                                      
                                      Page View：2364
                                  
                                    
          
                                   
          Adobe
          LONDON — GSK said Tuesday it would purchase the asthma-focused drug developer Aiolos Bio for $1 billion upfront, the latest in a string of pharma acquisitions that are bolstering hopes for the industry’s year ahead.
          The deal includes up to another $400 million in payments if certain milestones are met.
          advertisement
          Aiolos was launched just last year, based in both San Francisco and London. The company, which announced a $245 million Series A round in October, has been readying a Phase 2 trial of its candidate AIO-001 in adult asthma.
          Get unlimited access to award-winning journalism and exclusive events.					
          Subscribe																						Log In															
                      
                              
          
                                 Previous article：

                                
                                          Readout Newsletter: Vertex, Biogen's Aduhelm, and Bristol updates
                                
                            
          Next article：  
                                      
                                          Biden outlines 'new path' to provide student loan relief after Supreme Court rejection
                                                                    
          

      
           
    


       
       
       
    
     
           
    
           
    
           
   
      
     
           
      
           
       
          Related articles